Eisai Buys U.S. Biotech AkaRx With Chinese And Indian Markets In Sight
This article was originally published in PharmAsia News
Executive Summary
Eisai plans to acquire U.S. biotech AkaRx for $225 million in a move that will give the Japanese outfit access to AKR-501, a novel small-molecule thrombopoietin mimetic under development to treat thrombocytopenia resulting from viral hepatitis and other problems